# Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

> **NCT02572843** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 68 (actual)

## Conditions studied

- NSCLC Non-small Cell Lung Cancer

## Interventions

- **DRUG:** MEDI4736 (anti-PD-L1)

## Key facts

- **NCT ID:** NCT02572843
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-16
- **Primary completion:** 2020-01-20
- **Final completion:** 2024-03-19
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02572843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02572843, "Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02572843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*